• Original Weight Loss Injection Peptide Retatrutide Mt2 Freeze-Dried Powder Llipid Dissolving Injection 1.5/3ml Weight Loss Pen
  • Original Weight Loss Injection Peptide Retatrutide Mt2 Freeze-Dried Powder Llipid Dissolving Injection 1.5/3ml Weight Loss Pen
  • Original Weight Loss Injection Peptide Retatrutide Mt2 Freeze-Dried Powder Llipid Dissolving Injection 1.5/3ml Weight Loss Pen
  • Original Weight Loss Injection Peptide Retatrutide Mt2 Freeze-Dried Powder Llipid Dissolving Injection 1.5/3ml Weight Loss Pen
  • Original Weight Loss Injection Peptide Retatrutide Mt2 Freeze-Dried Powder Llipid Dissolving Injection 1.5/3ml Weight Loss Pen
  • Original Weight Loss Injection Peptide Retatrutide Mt2 Freeze-Dried Powder Llipid Dissolving Injection 1.5/3ml Weight Loss Pen

Original Weight Loss Injection Peptide Retatrutide Mt2 Freeze-Dried Powder Llipid Dissolving Injection 1.5/3ml Weight Loss Pen

Application: Weight Loss
Disposable: Non-Disposable
Gender: Unisex
Side Effect: No
Usage: Injection
Pharmaceutical Technology: Disinfection
Customization:
Manufacturer/Factory, Trading Company
Gold Member Since 2023

Suppliers with verified business licenses

Hebei, China
Fast Delivery
The supplier can deliver the goods within 15 days
Low MOQ
The MOQ for the supplier's products is 1
to see all verified strength labels (10)
  • Overview
  • Product Description
Overview

Basic Info.

Model NO.
Ozempic1.5/3ml
Efficacy
Weight Loss & Slimming
Group
Aldult
Applies to
Hospital Clinic Individual
Feature
Lose Fat and Lose Weight
Disposable.
Disposable
Transport Package
Packing with Ice Bags Inside
Specification
1piece/box, 5piece/box
Trademark
Ozempics
Origin
Korea
Production Capacity
100000pieces/Year

Product Description

Original Weight Loss Injection Peptide Retatrutide Mt2 Freeze-Dried Powder Llipid Dissolving Injection 1.5/3ml Weight Loss Pen
Product Description
 

 

The FDA granted approval for  for the treatment of chronic weight management, combined with a reduced-calorie diet and physical activity, in December 2014.

The drug is designed for adults with obesity (body mass index (BMI) >30) or overweight (BMI >27) and also affected with one obesity-related condition such as type 2 diabetes, cardiovascular disease, hypertension or high cholesterol.

In April 2020, a supplemental indication for the drug received approval from the FDA for chronic weight management in obese patients aged 12 years and older.

In March 2021, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use recommended the use of the drug for treating obesity in adolescents aged 12-17 years.

Original Weight Loss Injection Peptide Retatrutide Mt2 Freeze-Dried Powder Llipid Dissolving Injection 1.5/3ml Weight Loss Pen
Obesity and its prevalence
Obesity is a weight-related disorder that affects more than a third of adults in the US. The condition can be measured using BMI, the measurement of body fat based on the person's height and weight.

Obesity can lead to several health issues, including heart disease, type 2 diabetes and certain cancers, and results in a decreased life expectancy.

It is estimated that 80 million adults in the US suffer from obesity.

mechanism of action
contains an active component called liraglutide, which is a glucagon-like peptide-1 (GLP-1) analogue. The drug, which can be administered intravenously, reaches activated neurons in brain regions and regulates the appetite and calorie intake.

 contains an active component called liraglutide, which is a glucagon-like peptide-1 (GLP-1) analogue. The drug reaches activated neurons in brain regions, and regulates appetite and calorie intake."

Clinical trials on 

The FDA's approval of  was based on results from three Phase III clinical trials, known as SCALE (Satiety and Clinical Adiposity−Liraglutide Evidence in Nondiabetic and Diabetic people) studies, which were conducted for 56 weeks to evaluate the drug's safety and efficacy.
Original Weight Loss Injection Peptide Retatrutide Mt2 Freeze-Dried Powder Llipid Dissolving Injection 1.5/3ml Weight Loss PenOriginal Weight Loss Injection Peptide Retatrutide Mt2 Freeze-Dried Powder Llipid Dissolving Injection 1.5/3ml Weight Loss PenOriginal Weight Loss Injection Peptide Retatrutide Mt2 Freeze-Dried Powder Llipid Dissolving Injection 1.5/3ml Weight Loss PenOriginal Weight Loss Injection Peptide Retatrutide Mt2 Freeze-Dried Powder Llipid Dissolving Injection 1.5/3ml Weight Loss Pen

Product Description

A new long-acting glucagon-like peptide-1 (GLP-1) analogue from Novo Nordisk for glycemic control in adults with type 2 diabetes who have received metformin and/or sulfonylureas in addition to diet control and exercise. And reduce the risk of major cardiovascular adverse events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes with cardiovascular disease.
Original Weight Loss Injection Peptide Retatrutide Mt2 Freeze-Dried Powder Llipid Dissolving Injection 1.5/3ml Weight Loss PenOriginal Weight Loss Injection Peptide Retatrutide Mt2 Freeze-Dried Powder Llipid Dissolving Injection 1.5/3ml Weight Loss PenOriginal Weight Loss Injection Peptide Retatrutide Mt2 Freeze-Dried Powder Llipid Dissolving Injection 1.5/3ml Weight Loss Pen
 

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now

You Might Also Like

Gold Member Since 2023

Suppliers with verified business licenses

Manufacturer/Factory, Trading Company
Registered Capital
18800 RMB
Plant Area
<100 square meters